Skip to main content
RESMED INC logo

RESMED INC — Investor Relations & Filings

Ticker · RMD LEI · 254900O2VD7IQ5OGI615 ASX Manufacturing
Open in API
Filings indexed 1,641 across all filing types
Latest filing 2017-10-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX RMD

About RESMED INC

https://www.resmed.com

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s primary product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel machines, and a variety of masks and accessories designed to improve patient adherence and comfort. ResMed distinguishes itself through its focus on digital health, offering integrated software platforms that enable remote patient monitoring and data-driven clinical insights for healthcare providers. Additionally, the company provides software-as-a-service (SaaS) solutions to support out-of-hospital care settings, including home health, hospice, and skilled nursing facilities, aiming to improve patient outcomes and reduce overall healthcare costs.

Recent filings

Filing Released Lang Actions
Form 10Q for QTR ended September 30, 2017 27 pages 616.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and is described as a 'Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' for the quarterly period ended September 30, 2017. It contains detailed unaudited condensed consolidated financial statements, including balance sheets, income statements, cash flow statements, and notes to the financial statements. The document also includes management's discussion and analysis, risk factors, legal proceedings, and other information typical of a quarterly report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the actual quarterly report, not just an announcement or certification. Therefore, the appropriate classification is 'Interim / Quarterly Report' with code IR. Q1 2018
2017-10-29 English
ResMed Announces Results for the First Quarter of FY 2018 7 pages 294.2KB
Interim / Quarterly Report Classification · 98% confidence The document is a detailed announcement of financial results for the first quarter of fiscal year 2018 by ResMed Inc. It includes comprehensive financial data such as revenue, net income, earnings per share, operating expenses, cash flow statements, balance sheets, and reconciliations of GAAP and non-GAAP measures. The presence of detailed financial statements and analysis for a quarterly period (three months ended September 30, 2017) indicates this is a comprehensive interim financial report. The document also includes dividend declarations and webcast details for discussing the quarterly results, which is typical for an Interim / Quarterly Report. It is not merely an earnings release (which would be shorter and less detailed), nor is it an annual report or audit report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). The document length (over 14,000 characters) and detailed financial data confirm it is a full report, not just an announcement or summary. Q1 2018
2017-10-26 English
Dividend/Distribution - RMD 4 pages 33.5KB
Notice of Dividend Amount Classification · 100% confidence The document is a detailed announcement regarding a dividend distribution by ResMed Inc. It includes specific information such as the dividend amount, ex-date, record date, payment date, currency, withholding tax rate, and other dividend-related details. The content is focused solely on notifying shareholders about the dividend payment and its terms, without any financial statements or broader financial performance data. This matches the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and details for shareholders.
2017-10-26 English
FPH: Update on Patent Proceedings in Europe 1 page
Legal Proceedings Report Classification · 95% confidence The document is a stock exchange announcement providing an update on ongoing patent litigation proceedings in Europe involving Fisher & Paykel Healthcare and ResMed. It discusses court rulings, ongoing trials, and expected decisions related to patents. There is no financial data, no mention of financial results, no management discussion, no shareholder voting results, and no regulatory certifications. The content is focused on legal proceedings related to patents, which fits the category of Legal Proceedings Report. The document length is short (2095 characters), and it is not an announcement of a report publication but a substantive update on legal matters.
2017-10-12 English
ResMed to Announce First Quarter Fiscal Year 2018 Results 1
Regulatory Filings Classification · 95% confidence The document is a short announcement stating that ResMed will report its first quarter fiscal year 2018 results on a future date, including details about the webcast and replay. It does not contain any actual financial data or detailed results. The document length is only 2133 characters, which is quite short and consistent with an announcement rather than a full earnings release or report. According to the 'MENU VS MEAL' rule, this is an announcement of an upcoming earnings release, not the earnings release itself. Therefore, the appropriate classification is Earnings Release (ER) announcement, but since it is only announcing the date and webcast, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the earnings call timing, not the earnings release itself.
2017-09-28 English
Official notification of AGM (Proxy) 125 pages 867.2KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, which is used to solicit shareholder votes for an upcoming annual meeting. It includes detailed information about the meeting date, location, items of business to be voted on (such as election of directors, ratification of auditors, approval of executive compensation), voting instructions, and corporate governance information. The presence of terms like 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934', 'Definitive Proxy Statement', and detailed proposals for shareholder voting clearly identify this as a Proxy Solicitation & Information Statement. It is not an Annual Report, Earnings Release, or any other type of filing. The document length and content confirm it is the full proxy statement, not just an announcement or a brief notice. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2017-09-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.